Dysplasia News and Research

RSS

Dysplasia is a term used in pathology to refer to an abnormality in maturation of cells within a tissue. This generally consists of an expansion of immature cells, with a corresponding decrease in the number and location of mature cells.

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

Europe conference to discuss on new HIV indicator diseases

Today, heterosexuals in Europe are at particular risk of carrying HIV for so long that they remain undiagnosed until their immune system starts to fail and they become ill. An international study under the leadership of the HIV in Europe initiative has now revealed that a number of diseases, including herpes zoster and certain forms of cancer, should be on the list of indicators for having HIV - and thus serve to prompt health care professionals to suggest an HIV-test to their patients.

2 Mar 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Ultrasound reliable alternative to X-rays for DDH screening in children

Developmental dislocation (dysplasia) of the hip (DDH) is a common congenital condition in which a child's upper thighbone is dislocated from the hip socket. The condition can be present at birth or develop during a child's first year of life. Plain radiography (X-rays) has long been the gold standard screening modality for this condition in 6-month-old children, despite concerns over exposing very young children to ionizing radiation.

10 Feb 2012

Patients with GERD benefit from radiofrequency ablation

Heartburn. Acid reflux, GERD. They're different terms for the same type of condition - stomach acid used for digestion travels back up the esophagus, the "food pipe" that connects your throat to your stomach.

9 Feb 2012

Tobacco smoking may increase risk of esophageal cancer in Barrett's patients

Barrett's esophagus (BE) patients who smoke tobacco are at a two-fold increased risk of developing esophageal cancer, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. BE patients who smoke also double their risk for developing advanced precancerous cells.

31 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces results from azacitidine Phase 1 study on AML

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens.

12 Dec 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Asuragen announces data from microRNA biomarker study on pancreatic cancer

Asuragen, Inc. announced today that data from a collaborative study with Johns Hopkins regarding microRNA biomarkers for use on pancreatic cyst fluid specimens was presented at the American Pancreatic Association Annual Meeting being held November 2-5, 2011 in Chicago.

4 Nov 2011

New Mayo Clinic social network connects global community of esophageal cancer patients

In 2008, physicians at Mayo Clinic Florida led by Herbert Wolfsen, M.D., were looking for new ways to keep in touch with the large group of esophageal cancer patients cared for by him and other gastroenterologists and surgeons. Telephone calls, faxes and email had worked to create a network of patients but many now wanted interactive and remote access capability to share their experiences and challenges with this serious disease.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

Fierce Vaccines highlights Inovio's VGX-3100 as one of 10 Promising Therapeutic Vaccines

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon vaccine for treating cervical dysplasia and cancer caused by human papillomavirus, was highlighted by Fierce Vaccines as one of 10 Promising Therapeutic Vaccines.

31 Oct 2011

Narrow band imaging an equally effective alternative to chromoendoscopy for dysplasia

A new study from Spain finds that narrow band imaging appears to be a less time-consuming and equally effective alternative to chromoendoscopy for the detection of dysplasia (abnormal growths) in patients with long-standing inflammatory bowel disease.

13 Oct 2011

Angle-resolved low coherence interferometry can diagnose pre-cancerous colon cells

After demonstrating that light accurately detected pre-cancerous cells in the lining of the esophagus, Duke University bioengineers turned their technology to the colon and have achieved similar results in a series of preliminary experiments.

12 Oct 2011

VGX International, Inovio partner to co-develop SynCon vaccines for hepatitis B and C infections

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.

10 Oct 2011

UCLA scientists create mouse model for autism

UCLA scientists have created a mouse model for autism that opens a window into the biological mechanisms that underlie the disease and offers a promising way to test new treatment approaches.

30 Sep 2011